GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10th anniversary of its unique Equinoxe® Shoulder System.
The Equinoxe system’s platform design enables surgeons to convert from either a primary shoulder or fracture hemiarthroplasty to a reverse shoulder without stem removal. The primary system was launched in 2004, the reverse system was introduced in 2007 and the system now includes several proprietary glenoid options. The product line’s success continues to exceed company expectations, currently leading the industry as the fastest growing shoulder. Exactech has sold approximately 60,000 Equinoxe shoulders since the first surgeries on November 16, 2004.
“The Equinoxe system has been successful because a diverse group of surgeons and engineers collaborated to produce a unique product that solves clinical challenges,” said Darin Johnson, Vice President, Extremities and Hips at Exactech. “It is built on a biomechanically sound, anatomic design philosophy that provides intraoperative flexibility and unrivaled glenoid solutions for surgeons – all supported by dozens of publications and presentations at scientific meetings.”
Joseph Zuckerman, MD, one of the original design team members, stated, “We began the development of the Equinoxe system with the goal of designing an arthroplasty system that would enable surgeons to address the entire spectrum of complex clinical problems. I am very proud that Equinoxe has led the industry as the first shoulder design that allowed the surgeon to replicate a patient’s unique anatomy by independently adjusting parameters in situ. It has been a gratifying project because we have delivered on our original goal.”
“We started Exactech 30 years ago in order to solve clinical challenges with designs that improve patient outcomes,” said William Petty, MD, Executive Chairman of Exactech and one of the company’s founders. “I am especially proud that one of our best examples of this, the Equinoxe system, has now helped thousands of patients get back to the activities of daily life.”
Orthopaedic surgeons who want to learn more about the Equinoxe system and the latest techniques in shoulder replacement can take advantage of Exactech’s personalized medical education programs. Surgeons can design the workshop that best meets their individual preferences, including live surgery observation, hands-on courses, hospital in-service programs or in-depth technical review with Exactech staff at the corporate headquarters.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.